Stock Track | PegBio Plummets 6.96% Intraday Amid Lock-Up Expiry Concerns Following Partnership Rally

Stock Track

May 21

PegBio Co-B (02565.HK) experienced a significant intraday plummet of 6.96%, continuing its recent pullback after an explosive rally earlier in the week.

The decline is attributed to investor concerns over a share lock-up expiry period. This comes after the stock had surged over 100% following the company's announcement of a strategic commercialization partnership with Tengrui Pharma for its GLP-1 drug Paidakang (Vipeptanate Injection) targeting the Chinese mainland market.

Under the agreement with Tengrui Pharma, PegBio is set to receive approximately HK$140 million in licensing fees, with both parties targeting cumulative sales exceeding RMB 10 billion. The current retreat contrasts with gains in the broader biotechnology sector during the session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1152383118"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1152383118\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1152383118?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-21 10:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152383118","market":"sg","top_or_hot":-1,"title":"Stock Track | PegBio Plummets 6.96% Intraday Amid Lock-Up Expiry Concerns Following Partnership Rally","media":"Stock Track","content":"<p>PegBio Co-B (02565.HK) experienced a significant intraday plummet of 6.96%, continuing its recent pullback after an explosive rally earlier in the week.</p>\n<p>The decline is attributed to investor concerns over a share lock-up expiry period. This comes after the stock had surged over 100% following the company's announcement of a strategic commercialization partnership with Tengrui Pharma for its GLP-1 drug Paidakang (Vipeptanate Injection) targeting the Chinese mainland market.</p>\n<p>Under the agreement with Tengrui Pharma, PegBio is set to receive approximately HK$140 million in licensing fees, with both parties targeting cumulative sales exceeding RMB 10 billion. The current retreat contrasts with gains in the broader biotechnology sector during the session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | PegBio Plummets 6.96% Intraday Amid Lock-Up Expiry Concerns Following Partnership Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | PegBio Plummets 6.96% Intraday Amid Lock-Up Expiry Concerns Following Partnership Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-21 10:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>PegBio Co-B (02565.HK) experienced a significant intraday plummet of 6.96%, continuing its recent pullback after an explosive rally earlier in the week.</p>\n<p>The decline is attributed to investor concerns over a share lock-up expiry period. This comes after the stock had surged over 100% following the company's announcement of a strategic commercialization partnership with Tengrui Pharma for its GLP-1 drug Paidakang (Vipeptanate Injection) targeting the Chinese mainland market.</p>\n<p>Under the agreement with Tengrui Pharma, PegBio is set to receive approximately HK$140 million in licensing fees, with both parties targeting cumulative sales exceeding RMB 10 billion. The current retreat contrasts with gains in the broader biotechnology sector during the session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02565","symbol_name":"派格生物医药-B","start_time":0,"source_url":"","article_id":"1152383118","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152383118","pubTimestamp":1779329251,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"PegBio Co-B (02565.HK) experienced a significant intraday plummet of 6.96%, continuing its recent pullback after an explosive rally earlier in the week. The decline is attributed to investor concerns...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02565":"派格生物医药-B"},"translate_title":"个股追踪|PegBio盘中暴跌6.96%因合伙企业反弹后禁售期担忧","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02565":1},"content_text":"PegBio Co-B (02565.HK) experienced a significant intraday plummet of 6.96%, continuing its recent pullback after an explosive rally earlier in the week.\nThe decline is attributed to investor concerns over a share lock-up expiry period. This comes after the stock had surged over 100% following the company's announcement of a strategic commercialization partnership with Tengrui Pharma for its GLP-1 drug Paidakang (Vipeptanate Injection) targeting the Chinese mainland market.\nUnder the agreement with Tengrui Pharma, PegBio is set to receive approximately HK$140 million in licensing fees, with both parties targeting cumulative sales exceeding RMB 10 billion. The current retreat contrasts with gains in the broader biotechnology sector during the session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}